Prostate cancer is among the most common oncological diseases among the male population. Various specialists are involved in the diagnosis process. These are urologists, pathologists, medical oncologists. The histology (the microscopic appearance of the tumor), the degree of spread of the disease, the value of the tumor marker-PSA at the time of diagnosis, age and accompanying diseases are evaluated. To carry out this complex assessment, systems have been developed to determine the risk in patients already diagnosed with prostate cancer. Systems classify patients into 3 categories – low, medium and high risk. This is relevant to the choice of therapeutic approach, as well as to determining the risk of disease progression and fatal outcome. The CAPRA score has been put into practice and is an up-to-date digital risk assessment system based on 5 indicators: Age at diagnosis Under 50 years of age At 50 years of age or older 0 points 1 point PSA at diagnosis ( ng/ml) Less than or equal to 6. Between 6.1 and 10 Between 10.1 and 20 Between 20.1 and 30 Higher than 30 O points 1 point 2 points 3 points 4 points Biopsy Gleason score (primary/secondary) No rating 4 or 5 Secondary rating 4 or 5 /eg. 3+4/ Primary grade 4 or 5 /eg. 4+3/ 0 points 1 point 3 points Clinical stage (T stage) T1 or T2 stage T3a stage 0 points 1 point Percentage of biopsy specimens with tumor cells Less than 34% More than 34%, including 0 points 1 point Total dots: T stage indicates the local spread of the tumor. In T2, the malignant process develops within the gland, while in T3, the carcinoma passes the prostate capsule and infiltrates the surrounding tissues to varying degrees. The Gleason score is determined by a pathologist and indicates the degree of differentiation of malignant tissue. It is formed from two numeric values. The first shows the degree of differentiation of the predominant tumor tissue, the second value – of the smaller component of the total tumor mass. The CAPRA rating is formed by summing the points corresponding to the values ​​of the 5 monitored indicators. Examples: Patient 1: 56-year-old man /1 item/ with PSA level – 8.2 /1 item/, Gleason score – 3+4 /1 item/, clinical stage – T3a /1 item/, tumor cells in 2 of 8 biopsy samples (25%) /0 pts/ has a CAPRA score of 4. Patient 2: 46-year-old man /0 pts/ with a PSA level of 16.3 /2 pts/, score according to Gleason – 4+3 /3 pts/, clinical stage – T1c /0 pts/, tumor cells in 6 out of 10 biopsy samples (60%) /1 pt/ has a CAPRA score – 6. NEWS_MORE_BOX In the low category risk includes patients with a CAPRA score of 0 to 2, medium is a sum of 3 to 5, and high is between 6 and 10. The classification of patients into categories (low, medium, and high risk) is relevant to the choice of a therapeutic plan, as well as to the expected results after carrying out a specific treatment (surgery, radiotherapy, hormone therapy, chemotherapy, etc.).The lowest-risk patients are subject to active surveillance. Intermediate-risk patients undergo surgery or radiotherapy with or without endocrine therapy. High risk necessitates the application of a sequence of different therapeutic approaches. Although the CAPRA score has proven to be effective, it cannot replace individualized decision-making about the treatment plan in men with prostate cancer.